We reviewed the results of repeated sample submissions within a 7-day time frame for Clostridium difficile toxin testing. A total of 2,940 samples were tested during a 3-month period using a cell culture cytotoxicity assay (CCCA). The results from all second samples (n ‫؍‬ 1,101) were concordant with the original test result. In only two cases (0.8%; n ‫؍‬ 247) was a third sample positive when the first two samples were negative. In this study, submission of multiple samples for CCCA did not increase detection of Clostridium difficile infection.
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Clostridium difficile is a leading cause of diarrhea in patients who have received antimicrobials and chemotherapeutic treatments. In the era of shrinking laboratory resources, the timely, accurate diagnosis of C. difficile continues to be a challenge. A variety of testing options are available. These include anaerobic culture on selective media, direct toxin testing for either toxin A alone or both toxins A and B, detection of C. difficile antigen with subsequent toxin testing of positive samples, and finally nucleic acid amplification techniques. Each of these methods has advantages and disadvantages (1-4, 7, 9) .
Direct toxin testing is the most frequently used approach. Cell culture systems that are sensitive to the effects of toxin followed by neutralization of cytopathic effect have been the gold standard. Analytical sensitivity of the cell culture cytotoxicity assay (CCCA) is as low as 10 pg of toxin (4) . Such testing requires the availability of cell culture lab facilities and skilled personnel. In addition, this system is labor-intensive and may require up to 72 h for a final result. For these reasons, many labs have abandoned CCCA in favor of enzyme immunoassays (EIAs). In general, EIAs are less sensitive than CCCA (2) (3) (4) 7) .
A previous publication from this tertiary-care, urban medical center reported the value in testing multiple samples from patients when an EIA is used (5) . In the attempt to overcome perceived suboptimal recovery, the laboratory received two, three, or more samples per week. After a series of problems related to consecutive use of two commercial toxin A/B EIAs in our laboratory, a decision was made to return to testing with an in-house CCCA previously reported to be more sensitive than an EIA method (5) . The purpose of this study was to determine the utility of multiple sample submissions when a CCCA is used.
CCCA was performed using a modified version of an inhouse procedure (5, 6) . In brief, stool specimens were diluted 1:5 in sterile phosphate-buffered saline. Specimens were mixed by vortexing and were centrifuged at 4,000 rpm at 4°C for 30 min. Supernatants were filter sterilized through an 0.45-m membrane filter (Millipore, Billerica, MA). Dilutions of the stool filtrates and positive control toxin (1:2 and 1:10) were prepared with sterile phosphate-buffered saline and antitoxin.
Twenty microliters of each dilution of control toxin, control toxin plus antitoxin, stool filtrate, and stool filtrate plus antitoxin was added to duplicate wells of microtiter plates containing confluent human foreskin fibroblast cells (Diagnostic Hybrids, Inc., Athens, OH). Thus, the final dilutions tested were 1:60 and 1:300. The plates were incubated at 37°C in 5% CO 2 and were read for cytopathic effect at 24 and 48 h. Dilutions of toxin control reagent mixed with buffer were observed for the expected cell rounding in the 1:60 and 1:300 dilutions. Dilutions of toxin control reagent mixed with antitoxin were observed for neutralization in the 1:60 and 1:300 dilutions. In mixtures containing dilutions of fecal filtrate plus buffer, Ն50% cell rounding indicated the presence of cytotoxic activity. If this was neutralized in dilutions of fecal filtrate plus antitoxin, the presence of C. difficile toxin was confirmed. All consecutive stool samples with sufficient volume were accepted for testing 7 days per week.
All CCCA results over a 3-month period were reviewed for multiple requests within 7 days. All data were entered into EXCEL and analyzed using STATA version 7.0.
There were 2,940 samples tested from 670 patients. Overall, there were 219 positives from 141 different patients for a sample positivity rate of 7.4%. In 1,101 instances a second sample from the same patient was submitted within 7 days. Of those 1,101 instances, two consecutive samples were negative for 1,063 specimens and in 38 instances both were positive. The first two samples were 100% concordant (Table 1) . Two hundred forty-seven patients were tested using a third sample during the same week. For 245 of these 247 patients, results of the third sample matched the results of the initial two samples. Two hundred thirty-eight patients were negative, and nine were positive. Of the nine positive samples, two were first-time positives. Thus, 2 of the 247 patients (0.8%) had a third sample whose result was positive, compared to the initial two samples, whose results were negative in the same week. Chart review revealed that neither patient was treated. One patient had a gastrointestinal hemorrhage related to a polyp. Sigmoidoscopy, performed to evaluate the bleeding, did not reveal pseudomembranous colitis or other mucosal abnormalities. The second patient had diarrhea postoperatively, but there was no mention of suspicion of antibiotic-associated diarrhea.
Rejection of the third or more sample per week would decrease the annual volume by 1,080 tests. The supply expense per test is $13.00, resulting in a $14,040 savings. The technologist time per test is 35 min, resulting in a labor saving of 630 h. Testing one sample per week would decrease the annual volume by 4,404, saving $57,252 in supply expense and 2,569 h of labor.
During this time, there were 37% repeat samples. As these data show, when the CCCA is used, there is reasonable certainty of the accuracy of the result from the first sample tested. Testing a second sample within 7 days did not yield a different result in any instance. Submission of a third sample resulted in detection of a first positive result in only two cases (0.8%).
Current practice guidelines recommend submission of additional specimens for C. difficile toxin if a single sample is negative and clinical suspicion is high (2, 3) . Few papers, however, have analyzed the benefit or cost-effectiveness of such recommendations. An initial study from our institution demonstrated increased sensitivity of C. difficile detection with submission of a second sample at a time when the lab was using an insensitive EIA method (5) . The results of the current study, using a more sensitive CCCA method, are similar to those reported by Renshaw et al. (8) . In a study of 4,238 specimens from 2,009 patients submitted for C. difficile toxin testing using CCCA, 36% represented repeated tests. New information was provided in only 0.5 to 0.8% of cases (8) . The authors of that study likewise concluded that repeat CCCA should not be performed within 7days of the initial test (8) .
The practice of sending multiple C. difficile toxin test samples is not warranted when CCCA is used. In our institution, such behavior likely arose from use by the laboratory of a less sensitive and less reproducible method for C. difficile toxin detection and data that supported the value of repeated testing when an EIA method was used (5) . In addition, some of our clinicians had the mistaken perception that three negative C. difficile toxin results were required for nursing home placement. Compliance with a policy of rejection of duplicate samples within a 7-day period has been successful with presentation of the above data to medical staff and clarification of state rules and regulations regarding nursing home placement of C. difficile-positive patients. 
